Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
India · Delayed Price · Currency is INR | Market Cap | 553.85B |
| Revenue (ttm) | 134.56B |
| Net Income (ttm) | 7.54B |
| Shares Out | 282.20M |
| EPS (ttm) | 26.70 |
| PE Ratio | 73.51 |
| Forward PE | 22.49 |
| Dividend | 2.50 (0.13%) |
| Ex-Dividend Date | Oct 3, 2025 |
| Volume | 349,585 |
| Average Volume | 657,006 |
| Open | 1,970.00 |
| Previous Close | 1,971.20 |
| Day's Range | 1,948.10 - 1,973.40 |
| 52-Week Range | 1,275.50 - 2,284.80 |
| Beta | 0.29 |
| RSI | 41.82 |
| Earnings Date | Nov 7, 2025 |
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides branded, OTC, and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, immunology, pain management, hypertension, central nervous system, cardiology, diabetes, contraceptives, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injec... [Read more]
Financial Performance
Financial StatementsNews
Glenmark Pharma board declares Rs 2.50 interim dividend for FY26
Glenmark Pharmaceuticals Limited has announced an interim dividend for the financial year 2025-26. In a board meeting held on Friday, 26th September 2025, the company approved an interim dividend of ₹...
Glenmark Pharma shares fall over 2% after Trump announces 100% tariff on branded drugs
Shares of Glenmark Pharmaceuticals Ltd slipped 2.33% to ₹1,983.40 in Friday’s session, September 26, as Indian pharmaceutical stocks came under pressure following U.S. President Donald Trump’s announc...
Nomura maintains neutral on Glenmark Pharma with Rs 1,500 target price, says oncology licensing deal adds long-term growth
Nomura has maintained its neutral rating on Glenmark Pharma with a target price of ₹1,500 after the company announced an in-licensing agreement with Hengrui Pharma for Trastuzumab Rezetecan, an oncolo...
Top stocks to watch today, September 25: Tata Motors, NTPC, Glenmark Pharma, Newgen Software, Lupin and more
Indian markets are expected to stay volatile today, September 25, with several major corporate announcements and developments likely to drive stock-specific action. Here are the top stocks to watch in...
Stock market live updates today: Indian share market updates, Sensex & Nifty on 25 Sept 2025
Welcome to Business Upturn’s live coverage of the Indian stock market on Thursday, 25 September 2025. The trading session is expected to remain stock-specific as several companies announced key develo...
Glenmark Pharma secures $1.1B deal with Hengrui for exclusive global rights to HER2-targeted therapy Trastuzumab Rezetecan
Glenmark Pharmaceuticals Ltd., through its wholly-owned subsidiary Glenmark Specialty S.A. (GSSA), has entered into a landmark exclusive license and collaboration agreement with Hengrui Pharma for Tra...
Glenmark Pharma enters licensing pact with Astria; positive early results from STAR-0310 trial: Report
Glenmark Pharmaceuticals Ltd is in focus after multiple reports confirmed that the company has entered into a licensing agreement with U.S.-based Astria Therapeutics for the development of monoclonal ...
Glenmark Pharma shares jump over 2% after its subsidiary gets $700 million from AbbVie for licensing deal
Glenmark Pharma shares jumped over 2% in early morning trade after the company announced that its wholly owned subsidiary, Ichnos Glenmark Innovation (IGI), has received an upfront payment of $700 mil...
Glenmark Pharma receives $700 million upfront payment from AbbVie for global licensing deal
Glenmark Pharmaceuticals announced that its wholly owned subsidiary, Ichnos Glenmark Innovation (IGI), has received an upfront payment of $700 million from AbbVie (NYSE: ABBV). The payment follows thr...
Glenmark Pharma initiates multi-country Phase 3 Clinical Trial for Envafolimab in Stage III NSCLC
Glenmark Pharmaceuticals Ltd., a leading research-driven global pharmaceutical company, has announced the initiation of a multi-country Phase 3 clinical trial for Envafolimab, an innovative subcutaneo...
Bajaj Electricals, UBL& more: Top stocks on brokers' radar today
Brokerage firms have issued varied ratings on several companies. HSBC maintains a buy rating on Glenmark Pharma, anticipating IGI to become self-funding and highlighting key FDA clearances. CLSA has a...
Glenmark Pharma shares jump over 2% as HSBC maintains ‘Buy’ rating with target price of Rs 2,380
Glenmark Pharmaceuticals shares climbed over 2% after HSBC maintained its buy rating on the stock, setting a target price of ₹2,380 per share. The brokerage highlighted the company’s progress in innov...
Glenmark Pharma share: HSBC maintains buy with Rs 2,380 target, highlights catalysts in debt reduction and FDA approvals
HSBC has reiterated its buy rating on Glenmark Pharmaceuticals with a target price of ₹2,380 per share, pointing to progress at its innovation arm, steady deleveraging and key regulatory catalysts as ...
Stocks to watch on brokerages today, September 3: ITC, Adani Power, Indus Towers, UBL, Glenmark Pharma and more
Several brokerage firms have issued their latest recommendations for top companies across sectors, offering insights for investors looking to track potential market movers today. Indus TowersCLSA has ...
Glenmark Pharma to launch Eribulin Mesylate Injection in the US market
Glenmark Pharmaceuticals Inc., USA, has announced the upcoming launch of Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials, set to begin distribution in September 2025. This launch ...
Glenmark Pharma to launch Micafungin for Injection USP in the US market
Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals Ltd., has announced the upcoming launch of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial). The...
Top stocks to watch today, August 18: JK Cement, Swiggy, KEC International, Alembic Pharmaceuticals, Glenmark, auto stocks and more
Markets will track sector-specific developments and company announcements on Monday, August 18. Key updates span GST rationalisation measures, capex plans, earnings, and trade duty recommendations. Po...
Nomura maintains neutral on Glenmark Pharma, trims outlook after Q1 miss and exceptional charges
Nomura has maintained its neutral rating on Glenmark Pharmaceuticals with a target price of ₹1,500 after the company reported weaker-than-expected first-quarter results. Revenue and EBITDA missed the ...
Q1FY26 earnings calendar for August 14: Ashok Leyland, Glenmark, IDEA, IOC, Hindustan Copper, Patanjali, EaseMyTrip to announce results
The Q1FY26 earnings season continues in full swing, with a packed line-up of companies scheduled to release their financial results on Thursday, August 14, 2025. Among the key names to watch are auto ...
Nomura remains neutral on Glenmark, says near-term upside for stock captured post ISB-2001 deal
Nomura has reiterated its ‘Neutral’ rating on Glenmark Pharmaceuticals, maintaining a target price of ₹1,500. This comes after the company held its post-earnings analyst meeting, where management comm...
Top stocks to buy: Stock recommendations for the week starting July 14, 2025 - check list
Stock market recommendations: Motilal Oswal Financial Services recommends Suzlon and Glenmark Pharma as top stock picks for the week starting July 14, 2025. Suzlon anticipates healthy order inflows, p...
Top stocks in focus on July 14; DMart, Glenmark Pharma, VIP Industries, NCC, RITES, Ajmera Realty and more
Indian benchmark indices Sensex and Nifty 50 are expected to start lower on Monday, July 14, 2025, following mixed global cues. Here are some stocks likely to be in focus during the day’s trade: NCC L...
HSBC raises Glenmark Pharma share price target to Rs 2,275 on $1.9 billion AbbVie licensing deal
HSBC bullish on Glenmark Pharmaceuticals with a ‘Buy’ rating and has raised its target price to ₹2,275 per share, citing the company’s landmark out-licensing deal with global biopharma major AbbVie fo...
Glenmark Pharma receives warning letter from US FDA for Indore facility
Glenmark Pharmaceuticals has received a warning letter from the United States Food and Drug Administration (US FDA) concerning its manufacturing facility in Indore, Madhya Pradesh. The regulatory acti...
Glenmark Pharma shares surge 10% after its subsidiary signs $700 million licensing deal with AbbVie for ISB 2001
Glenmark Pharmaceuticals witnessed a sharp 10% rise in its stock price during morning trade after announcing a major licensing agreement between its US-based innovation subsidiary, IGI Therapeutics SA...